Promacta gets Priority Review in first-line anemia

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE